vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $16.9M, roughly 1.7× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -67.6%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
FVCB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $28.1M |
| Net Profit | — | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 43.7% | -147.6% |
| Net Margin | — | -147.1% |
| Revenue YoY | 4377.5% | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.31 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $28.1M | ||
| Q3 25 | $416.0K | $32.5M | ||
| Q2 25 | $15.8M | $15.7M | ||
| Q1 25 | $382.0K | $8.0M | ||
| Q4 24 | $378.0K | $86.6M | ||
| Q3 24 | $412.0K | $2.1M | ||
| Q2 24 | $415.0K | $500.0K | ||
| Q1 24 | $359.0K | $0 |
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $5.6M | $-51.2M | ||
| Q2 25 | $5.7M | $-44.9M | ||
| Q1 25 | $5.2M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $4.7M | $-19.1M | ||
| Q2 24 | $4.2M | $-12.5M | ||
| Q1 24 | $1.3M | $-10.3M |
| Q4 25 | 43.7% | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | 45.9% | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | -147.1% | ||
| Q3 25 | 1341.1% | -157.4% | ||
| Q2 25 | 36.0% | -285.6% | ||
| Q1 25 | 1352.1% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 1133.3% | -925.0% | ||
| Q2 24 | 1001.2% | -2503.2% | ||
| Q1 24 | 373.3% | — |
| Q4 25 | $0.31 | $-0.41 | ||
| Q3 25 | $0.31 | $-0.52 | ||
| Q2 25 | $0.31 | $-0.46 | ||
| Q1 25 | $0.28 | $-0.35 | ||
| Q4 24 | $0.27 | $0.52 | ||
| Q3 24 | $0.25 | $-0.20 | ||
| Q2 24 | $0.23 | $-0.13 | ||
| Q1 24 | $0.07 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $253.6M | $114.3M |
| Total Assets | $2.3B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $253.6M | $114.3M | ||
| Q3 25 | $249.8M | $147.7M | ||
| Q2 25 | $243.2M | $192.3M | ||
| Q1 25 | $242.3M | $229.0M | ||
| Q4 24 | $235.4M | $256.8M | ||
| Q3 24 | $230.8M | $201.0M | ||
| Q2 24 | $226.5M | $215.2M | ||
| Q1 24 | $220.7M | $223.9M |
| Q4 25 | $2.3B | $327.7M | ||
| Q3 25 | $2.3B | $372.8M | ||
| Q2 25 | $2.2B | $313.5M | ||
| Q1 25 | $2.2B | $327.3M | ||
| Q4 24 | $2.2B | $351.2M | ||
| Q3 24 | $2.3B | $217.6M | ||
| Q2 24 | $2.3B | $222.0M | ||
| Q1 24 | $2.2B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-43.5M |
| Free Cash FlowOCF − Capex | $23.8M | — |
| FCF MarginFCF / Revenue | 140.7% | — |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $-43.5M | ||
| Q3 25 | $7.6M | $-47.0M | ||
| Q2 25 | $3.3M | $-39.6M | ||
| Q1 25 | $5.4M | $-40.7M | ||
| Q4 24 | $18.2M | $42.0M | ||
| Q3 24 | $4.7M | $-14.5M | ||
| Q2 24 | $1.6M | $-7.3M | ||
| Q1 24 | $7.2M | $-6.7M |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | $-47.2M | ||
| Q2 25 | $3.3M | $-39.6M | ||
| Q1 25 | $5.4M | $-40.8M | ||
| Q4 24 | $18.1M | $41.7M | ||
| Q3 24 | $4.6M | $-14.6M | ||
| Q2 24 | $1.5M | $-7.3M | ||
| Q1 24 | $7.1M | $-6.8M |
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | -145.4% | ||
| Q2 25 | 20.8% | -252.2% | ||
| Q1 25 | 1413.6% | -512.1% | ||
| Q4 24 | 4786.0% | 48.2% | ||
| Q3 24 | 1121.8% | -706.3% | ||
| Q2 24 | 361.2% | -1463.4% | ||
| Q1 24 | 1988.3% | — |
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 0.2% | 0.6% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 37.3% | 0.3% | ||
| Q3 24 | 14.1% | 6.8% | ||
| Q2 24 | 12.8% | 7.6% | ||
| Q1 24 | 3.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
